About the report
The analysis is split into:
-
- The Drug Landscape: A deep-dive into all 2400+ assets in the Bispecific database by drug phase and status, disease indication and more, with a spotlight on top targets and combinations of drugs investigated in H2 2023.
- The Trial Landscape: An analysis of the 1800+ clinical trials tracked on Beacon Bispecific and a deeper look into trends surrounding disease indications and therapeutic classes.
- The Commercial Market: A deep dive into the data from the Beacon Deals and Companies database. Explore the successful partnerships of 2023, and the strategies behind them.
- The Future of the Bispecific Space: A look at the possibilities within the bispecific market based on preclinical data, plus a list of assets you should be looking out for this year.
- Regulatory Announcements: A comprehensive review of every regulatory announcement from 2023.
You may also be interested in...
H1 2024 Bispecific Landscape Review
Unlocking the Potential of Bispecific ADCs
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated Bispecific account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
